This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Vitamin K-dependent gamma-carboxylase.
Human | |
---|---|
Gene Name: | GGCX |
Uniprot: | P38435 |
Entrez: | 2677 |
Belongs to: |
---|
vitamin K-dependent gamma-carboxylase family |
EC 4.1.1.90; gamma-glutamyl carboxylaseFLJ26629; GC; Peptidyl-glutamate 4-carboxylase; Vitamin K gamma glutamyl carboxylase; vitamin K-dependent gamma-carboxylase; VKCFD1
Mass (kDA):
87.561 kDA
Human | |
---|---|
Location: | 2p11.2 |
Sequence: | 2; NC_000002.12 (85544720..85561527, complement) |
Endoplasmic reticulum membrane; Multi-pass membrane protein.
If you're interested in learning more about Anti-GGCX antibodies, you've come to the right place. This article will discuss how this antibody works, how it can be used to test human samples, and Steven Boster's background. The information in this article can help you to decide whether or not this marker is right for your research. We'll also discuss how this antibody reacts with human, mouse, and rat samples.
The Anti-GGCX Marker in Bosterland Bio is a human antibody designed for detection of the GGCX protein in the body. The Boster Bio antibody is a high affinity primary antibody and has been validated by the scientific community in many studies. It reacts with Human and Mouse samples and can be stored at -20 or 4 degrees Celsius. The Boster Bio antibody contains Trehalose and is available in both a 1 mg and 10 mg kit. The product is highly effective for testing multiple biological processes.
The Fce RI has an affinity for IgE and is expressed on many different cell types, including eosinophils, monocytes, and Langerhans cells. While the a-chain of IgE is the most common type of IgE antibody, the Fce RI is expressed on other cell types as well, including ciliated epithelial cells.
The GGCX peptide is incorporated into nanodiscs to provide a stable, catalytically active surface. Researchers then used hydrogen/deuterium exchange mass spectrometry to identify the regions of the nanodisc-incorporated GGCX that underwent structural rearrangement upon binding to propeptides. The regions of high binding affinity to the propeptide were identified at the C-terminal region.
Using this new technique, the antibodies were purified by protein G affinity chromatography, allowing them to recognize the target antigen. The antibodies were then tested against a number of synthetic peptides to assess their conformational specificity. These antibodies are highly specific for hGRP-F1 and c-carboxylated GRP. They also display different patterns of protein accumulation, which can lead to a greater number of potential applications.
Molecular analysis of the CDR H3 sequences of the human IgM peptide revealed that most of the antibodies were grouped into three groups based on their origins. These groups likely evolved from clonal expansion of a founder B cell that expressed a primary antibody with the primordial CDR H3. This means that all LCs paired with 17D8 HCs correspond to pre-rearranged 17D8 LCs.
The underlying mechanism of affinity maturation is selection for antibody that binds to a specific antigen. This method involves generation of mouse models specific to each prototype antibody. These mice models are critical tools for the antibody generation process. These antibodies could also serve as a starting point for the antibody generation process in humans. However, the primary antibodies still exhibit weak interactions with PD-1. It may be necessary to develop a panel of anti-PD-1 antibodies with corresponding amino acid changes.
The GRP splice transcript expression in cancerous and control tissue samples was correlated with the expression of MGP, GGCX, and VKOR genes. The expression of these genes was also correlated with tumor markers, such as OPN and TNFa. Moreover, the expression of GRP and VKOR was significantly increased in cancerous samples. The findings suggest that high-affinity primary antibodies targeting the GGCX marker may be an excellent approach to cancer diagnosis.
In a recent study, researchers isolated anti-PD1 antibodies from mouse models. These antibodies also bind to PD-1 ligands, demonstrating that PD1-antibody interaction is possible through these antibodies. While these findings are promising for further research, these antibodies should be tested before being approved for clinical trials. With further studies, the GGCX marker will be used to further investigate their potential as an immunotherapy tool.
There are many landmarks from Steve Boster's history. First, he founded a business that developed hundreds of primary antibodies. His innovations made his company one of the leading catalog antibody manufacturers in China by the late 90s. Now, his company provides high-sensitivity ELISA kits through a proprietary ELISA platform called PicoKine. This platform is made possible through Steven Boster's trade secrets. This platform has a wide range of advantages, including a fast turnaround time and reduced costs.
The late Steven Boster passed away on Sunday, June 26, 2022. He was a member of Concordia Hall in Staunton, VA. He was the son of James and Evelyn Meier Boster. He served in the U.S. Army during the Korean War and was a member of the Concordia Hall in Staunton. His family includes 2 Daughters, Natosha Peck and Crystal Boster; 6 Grandchildren; 4 Brothers, Jack and Sandy Boster; and sister Lisa Milton. Steve is also survived by many nieces and nephews.
PMID: 1749935 by Wu S.-M., et al. Cloning and expression of the cDNA for human gamma-glutamyl carboxylase.
PMID: 9166845 by Wu S.-M., et al. Genomic sequence and transcription start site for the human gamma- glutamyl carboxylase.